Yuhan Yanghang Signs Domestic Supply Contract with Bayer Korea for 'Bepanthen' and 'Canesten'

Yuhan Corporation and Bayer Korea Sign Domestic Supply Contract
Co-promotion of "Bepanthen Ointment" and "Canesten" Begins in February
Expanding Market Share in Skin Disease and Women's Health Sectors

At the contract signing ceremony for the supply of Bepanthen and other products between Yuhan Corporation and Bayer Korea, Oh Young-kyung, CEO of Bayer Korea (left), and Cho Wook-je, CEO of Yuhan Corporation, are taking a commemorative photo. Photo by Yuhan Corporation

Yuhan Corporation announced on the 24th that it signed a domestic supply contract for 'Bepanthen® Ointment' and 'Canesten®' with Bayer Korea on the 21st.

The supply contract signing for Bepanthen® Ointment and Canesten® took place at Yuhan Corporation's headquarters located in Dongjak-gu, Seoul. The signing ceremony was attended by executives and officials from both companies, including Jo Wook-je, CEO of Yuhan Corporation, and Oh Young-kyung, Head of Bayer Korea Consumer Health Division. Through this domestic supply contract, both companies will co-promote Bepanthen® Ointment and Canesten® products starting from February.

Bepanthen® Ointment is the first dexpanthenol-based non-steroidal dermatitis treatment and currently holds the number one global sales position in the dermatology field. It soothes sensitive skin and helps restore damaged skin barriers, making it widely used for treating various skin conditions across all ages, including diaper rash in infants, acute and chronic dermatitis (such as dry dermatitis), wounds, eczema, and sunburn.

Canesten® is an antifungal treatment with clotrimazole as its main ingredient, used for fungal infections on the skin surface and candidal vaginitis. It is available in various formulations such as cream, vaginal tablets, and powder. Notably, Canesten® is the world's top-selling treatment for candidal vaginitis and vulvitis, establishing itself as a representative product for managing women's health in daily life.

Yuhan Corporation expects to further expand its market share in the domestic treatment market for skin diseases and vaginitis/vulvitis for women's health through this contract. In particular, by combining Bayer Korea's global product lineup with Yuhan Corporation's sales capabilities, Bepanthen® Ointment and Canesten® will be made more accessible to a larger number of consumers.

Jo Wook-je, CEO of Yuhan Corporation, stated, "Bepanthen® Ointment and Canesten® are products that have proven their excellent quality worldwide and have significantly contributed to disease treatment globally. We hope that this agreement will create synergy between the strengths of both companies, enabling domestic consumers to more easily access products of world-class quality."

Oh Young-kyung, Head of Bayer Korea Consumer Health Division, said, "We are pleased to collaborate with Yuhan Corporation, which has excellent sales capabilities and a solid distribution network. We expect to enhance accessibility to Bayer products that allow for simpler and more effective management of various common skin and women's health conditions in daily life, thereby contributing to healthier daily lives for domestic consumers."